Q3 2022 Onconova Therapeutics Inc Earnings Call
[music].
Yeah.
Ladies and gentlemen, thank you for standing by and welcome to the uncle Noga Therapeutics third quarter 2022 financial results and business update conference call.
At this time all participants are in a listen only mode.
During managements prepared remarks, we will hold a question and answer session.
Good question at that time, Please press star followed by the number one on your telephone keypad.
If anyone has any difficulty hearing the conference. Please press star zero for operator assistance as a reminder, this call is being recorded today November 14th 2022 at this time I would like to turn the call over to Bruce Michael of lifestyle advisors.
Thank you operator, and welcome everyone to walking over third quarter 2022 financial results and update conference.
Conference call.
Earlier this afternoon <unk> issued a press release announcing its plans to conduct a phase <unk> clinical trial of Nevada cyclic combined with Letrozole in endometrial cancer and reported its financial results and business progress.
If you have not yet seen this press release it is available in the investors and media section of the company's website.
You Ww onto Nova Dotcom.
Following my introduction, we will hear from uncle Nova's, President and CEO , Dr. Steve Fruchtman Chief.
Keith Medical Officer, Dr. Mark Gelder, and Chief operating Officer, and Chief Financial Officer, Mark Guerin.
These prepared remarks, we will then be followed by a question and answer session.
Before turning the call over to aren't going out of his management team I would like to look and everyone that statements made during this call will include forward looking statements under the Safe Harbor provisions of the private Securities Litigation Reform Act of $19, 95, which involve risks and uncertainties that can cause.
Actual results to differ materially.
Forward looking statements speak only as of the date. They are made as the underlying facts and circumstances may change.
Except as required by law.
<unk> disclaims any obligation to update these forward looking statements to reflect future information events or circumstances for more information on forward looking statements. Please review the disclaimer in today's press release and the risk factors in the company's SEC filings with that I will now turn the call over to Steve.
Thank you Bruce and good afternoon everybody.
On today's call, we will focus predominantly on our two most recent and exciting pieces of news.
These relate to our newly announced plans to advance our lead asset, whereas this cycle and into a phase one dash to a trial.
And third line low grade endometrial and endometrial cancer.
And our recent presentation at the ESMO conference featuring updated data from an investigator.
Sponsored study.
Sure Tim.
Our CMO.
Medical officer, Dr. Mark Gelder grow into more detail on each of these points.
But I would first like to briefly outline the rationale underlying.
Endometrial cancer trial.
Which will evaluate <unk> in combination.
With the non steroidal aromatase inhibitor natural result.
Our decision to pursue this clinical program.
It's driven by three key factors.
First.
We recognize the endometrial cancer.
Arises in the uterine lining.
As an indication with a pressing on.
Medical need.
Improved therapies.
It is a large addressable patient population.
And in fact is the most common cancer of the female reproductive organs.
Low grade endometrial endometrial cancer.
Represents the target patient population for our newly announced clinical development program for a new ASIC cyclic.
Second we believe a clinical program evaluating <unk> in combination with Letrozole.
Endometrial cancer is a.
High probability of technical and regulatory success.
This belief is supported by clinical data.
That demonstrates the benefits of <unk>.
Brian and agent.
Hibbitts CDK four six pathway with Letrozole in this indication.
As a reminder, the RASM Franklin Potently inhibits CDK four and six alongside additional tyrosine kinase that play important roles in cancer cell growth.
A viable and metastasis.
Clinical data.
Dr <unk> will discuss in more detail.
Substantially de risks our upcoming trial.
Providing validation and clinical proof of concept.
<unk> mechanism of action.
Endometrial cancer.
The third and last driving factor behind our decision.
Conduct our upcoming clinical trial.
What is the opportunity to establish <unk> as a best in class therapy, when combined with Letrozole in recurrent endometrial cancer.
Well randomized phase III studies.
The average clinical proof of concept and compendium listings enable the off label use and reimbursement.
CDK four six inhibitors, such as <unk> in this setting.
The CDK <unk> inhibitors.
FDA approved in endometrial cancer.
And have several shortcomings related to safety.
Tolerability.
And primary and acquired drug resistance.
We believe there is a cycle can overcome these shortcomings based on data that we have generated net mark elder will highlight shortly.
Lastly, before handing the call off to mark to discuss our efforts.
<unk> cancer.
And recent <unk> data in more detail I'll give a very quick uptake.
<unk> of our trials.
Starting with neurology cyclin I'm pleased to say that safety data from the ongoing phase one solid tumor trials in both United States and China continued to be encouraging with a maximum tolerated dose.
Yet reached in either study.
Both of which are in the fifth.
Dose escalation cohort.
These trials are evaluating or as this cycle.
<unk> listed orally with two different schedules.
Miriam mirroring the administration schemes.
Through CDK, four and six inhibitors, which represent multi billion dollar drug franchises.
Well only approved.
<unk> receptor positive <unk> negative metastatic breast cancer.
Based on the.
The encouraging safety findings to date.
We and our partner in China, <unk> Bio Pharmaceuticals believe we may have the opportunity to dose escalate further in each trial.
Leaving us better positioned to drive efficacy in subsequent studies.
Accounting for the expected addition of dose escalation cohorts.
We now anticipate identifying a recommended phase two dose in the first half of 'twenty 'twenty three.
We anticipate the dose administration scheme.
<unk> in our phase one slash two.
<unk> study and our other studies being planned will be once daily continuous dosing of neurons are cyclical.
I want to point out.
Two out of three approved CDK <unk> inhibitors.
Most in a three week on.
One week off scheme.
This one week off requirement.
Potentially permits the tumor cells to proliferate during this week versus continuous.
Oppression of the cancer.
Daily dosing may provide.
Other CDK four six.
Asia is typically dose daily, but due to its half life.
<unk> twice daily dosing.
It appears that <unk> will be dosed once daily.
And continuously.
Looking forward, we remain interested in several indications for <unk> development.
Endometrial cancer as discussed on past earnings calls.
While it's too early to provide specifics on our clinical plans for these indications.
We can reiterate that.
Dk 46 inhibitor refractory hormone receptor positive <unk> negative metastatic breast cancer is an area of particular focus.
We recently identified a principal investigator and breast cancer International key opinion leader to lead the trial.
We look forward to providing further details as our clinical plans are finalized.
We have recently developed very encouraging data in mantle cell lymphoma cell lines with whereas the cyclists.
This data will be submitted to a.
A major medical meeting.
Shifting gears I will now briefly discuss Riga assertive.
Which as a reminder, as a multi faceted mechanism of action targeting the rash and polo like kinase, one pathways and the tumor immune microenvironment.
We are utilizing investigator sponsored trials to advance rigor.
In several indications.
And I'm, making impressive progress and will continue to present the data at medical meetings as we most recently did at the ESMO Conference.
In early 2023, we expect the initiation of an investigator sponsored phase II trial.
Evaluating <unk> in combination with the checkpoint inhibitor <unk> and checkpoint inhibitor refractory malignant melanoma.
In addition.
Investigator sponsored trial, a rigorous sort of mono therapy, and squamous cell carcinoma of the skin.
Shaded with recession.
Rick Epidermal license below so I'm really referred to as our Deb.
<unk> to enroll patients and was recently the subject of a non dilutive grant to continue.
Very important clinical trial in these desperate patients.
Initial single patient data in this ultra rare genetic disease indicates.
Continues to show a sustained complete response.
With the patient now on therapy for over 15 months.
In complete response, and we have additional patients being enrolled.
We believe this impressive response.
Okay.
<unk> Sir.
Yes.
Polo like kinase one may have important.
Rotations.
Both an odd associated Greg.
And other more prevalent squamous cell indications.
Given the central role of the <unk>.
Polo like kinase pathway in various cancers.
With that.
I'll now turn the Coca Cola with Doctor Gallagher to speak more about in a rather flat.
Ive coming endometrial cancer trial, and the recent ESMO presentation.
We got started and the Golar <unk> combination therapy.
K Ras mutated non small cell lung cancer.
Mark.
Okay.
Thanks, Steve.
And I'll begin by discussing our lead program the route the cycling.
Which is advancing towards a phase one why.
Two a study of.
The router type clip and Letrozole as combination therapy.
Second or third line recurrent metastatic low grade endometrial endometrial cancer or otherwise referred to as L. J E T.
The decision to move forward with a full clinical development program in the LG <unk> has been guided by Tencent phase two clinical data demonstrating the safety and clinical benefit.
Combining CV pay for six inhibitor with let result in this indication.
This includes the results of the N got inquiry and that's still probably a study that was presented by mirrors at ESMO in 2020.
This phase two study was a randomized double blind placebo controlled trial.
<unk> and <unk>, plus Letrozole vs Letrozole plus placebo.
Patients with estrogen receptor positive or ER positive advanced recurrent endometrial cancer.
Participants received what resolve orally.
Days, one through 28.
With either <unk> or placebo orally on days, one through 21 in 28 day cycles until disease progression.
Progression free survival or PFS was significantly improved with what resolve and Pablo cyclin.
Compared to left resolved plus placebo.
A hazard ratio of 0.56.
The median PFS of eight three months.
In the <unk>.
Paul will cycle with arm versus three months.
Placebo.
This difference in median PFS between groups.
Statistically significant with a P value of 0.0376.
In addition disease control rate at 24 weeks.
Also improved in the combination therapy group.
<unk> for the.
Mono therapy, or placebo group with values of 63.6, and 37, 8% respectively.
Safety data from the trial showed that the toxicity of Pablo cyclists and let resolve combination therapy was manageable and most patients remained on treatment until disease progression.
As anticipated.
<unk> emergent great three four hematologic adverse events with less resolved at.
Our cyclic or the most common aes observed, including neutropenia and anemia.
Dose reduction discontinuation of alpha cyclic once the required in 36 and 25% of patients respectively.
Of note I want to remind you that we have preclinical data.
Straightening in a head to head comparison.
Morocco, cyclin causes less neutropenia than power, both cycling and to date significant neutropenia has not been paid.
And our current phase one dose escalation trial with single agent <unk> cycle.
Importantly.
The promising findings of this randomized phase two trial with power both cyclic are consistent with the results of two other single arm phase two trials.
In patients with estrogen receptor positive endometrial cancer looking at let result in combination with the other two approved CDK four six inhibitors rigor cyclists.
<unk> cycle.
A recent data cut of the Obama cycle, plus let's resolve trial was presented at the 2022 Spo or society of Gynecologic Oncologist annual meeting in March 2022.
The pie of the trial reported on 30 patients.
Enrolled with a median follow up of 12 five months with nine of the patients still on study.
The disease control rate was 73% and the median progression free survival was nine one months.
Providing substantial evidence of a clinical benefit in patients with estrogen receptor positive recurrent or metastatic endometrial cancer.
In the single arm trial of rigor cyclic and let for salt combination therapy.
12 week progression free survival rate was 55% and relapse estrogen receptor positive endometrial cancer patients, which exceeded the trials prespecified success criteria.
Collectively these results strongly suggest no raza cyclical view provide clinical benefit to patients with advanced or recurrent L. GEC when combined with left resolved given its ability to inhibit CDK four and six.
Similar potency, but Paolo cyclin rigor cyclic and above aside.
Moreover, we have generated a.
Tensive preclinical data that indicates in RASM side may offer significant safety and efficacy advantages compared to these other agents.
Looking first at efficacy.
Preclinical data have demonstrated <unk> ability to suppress the growth of cancer cell lines resistant to powerful cyclists. In addition.
As the cycle has displayed potent inhibitory activity against our five.
And CSF, one receptor, which are not targeted by any of the approved.
Page four six inhibitors.
With Ian.
Yes.
Promoting anti tumor immunity.
Playing close so crucial roles and metastasis in cancer cell survival.
Doctors environments, we believe <unk> ability to inhibit these targets mainly to improved anti cancer activity.
<unk> durability of responses.
Returning our attention to the safety and Tolerability profile of the approved CDK four six inhibitors.
Start with Pablo cycling and rivals.
Both of these agents are associated with significant bone marrow suppression, which is a key dose limiting toxicity.
So it takes a three week on one week off treatment schedule.
With the RASM side, but we have not seen any clean clinically meaningful cases of bone marrow suppression, even with continuous daily dosing in our phase one program to date.
This highlights a potential safety advantage burned arises hike, but that may also contribute to improved efficacy.
Shipping a week of dosing every month may permit.
<unk> tumor cell proliferation, as Steve alluded to earlier.
Looking now at our banner cyclists.
The primary dose limiting toxicity for this agent as diarrhea.
This is a result of its affinity for the kinase GSK rebates, which.
Which is 29 times higher than that of neurosis cycle.
We believe the RASM side.
We will display an improved tolerability profile compared to about the cycle, allowing it to potentially be administered at a higher more effective dose.
Hypothesis is supported by clinical data from our phase one program as diarrhea has not been a dose limiting toxicity or high grade adverse events that we have seen to date.
Taken together, we believe the available clinical and preclinical data with their asthma cycling.
And currently approved CDK four six inhibitors, not only point to a high probability of technical and regulatory success for our endometrial cancer program, but also strongly suggest no.
As the cycle of successful development would provide patients with a much needed improved therapeutic options.
We look forward to beginning our multicenter trial, which will start with a dose escalation phase before moving to a phase two expansion cohort with approximately 30 patients.
A primary endpoint of 24 week progression free survival.
Our phase one two study in patients with LG E C will be up and running in the first quarter of 2023.
We anticipate interim data in the fourth quarter of 2023.
All patients will be treated with a continuous daily dose of both marasmus cyclic and letrozole.
Next I'd like to briefly turn the call its focus to rig a therapy and discuss the recent ESMO presentation, which Steve alluded to earlier.
Yes, no presentation.
Featured updated results from an investigator sponsored phase one slash two a trial evaluating oral rigo therapy in combination with the PD, one checkpoint inhibitor <unk> in patients with advanced <unk>.
Truda checkpoint inhibitor refractory.
<unk> mutated non small cell lung cancer.
Patients with Mek RAF mutation, we're eligible for the trial.
Efficacy data from the first 14 evaluable patients in the study revealed one complete response.
Partial response.
And one patient with stable disease per resist criteria.
We reported median duration of response.
We're 675 months.
With one partial response patients on study for 10 months and continuing without disease progression.
In addition, the <unk>.
<unk> two a achieved a complete response has been on studying for 10 plus months wildly maintaining an extra cranial complete response.
The disease control rate in these highly.
Refractory patients or the dose of <unk> equal to or above the minimally effective dose of 840 milligrams a day.
Combination with full dose the volatile Nab was 31%.
Collectively these data provide a signal of efficacy that we find highly encouraging, especially when considering two key aspects of the trial patient population.
First.
Frequent history of trial participants.
Over 80% have failed at least two lines of prior therapy and all.
<unk> have failed prior therapy with a checkpoint inhibitor and bullish about.
This last point is particularly significant as PD one is the target of all of that.
Fact that combining <unk> with nomad led to resist defined objective responses in these patients probably suggest that Regal circuit is synergistically enhancing the efficacy of the checkpoint inhibitor.
This hypothesis is consistent with preclinical data we have thus on past calls and is further supported by the observation of responses in patients who show low PD, one PDL one expression that diagnosis.
This feature typically portends resistant to checkpoint inhibitors like <unk> all of that and.
Suggests the role, Puerto Rico circuit and targeting the mutated Ras genes.
The second key aspect of the trials patient population I'll discuss relates to the various underlying K Ras mutations in these patients.
Unlike agents that target a particular favorite apps varian, such as GE 12 C but.
So we'll go to.
<unk> combination assay K Ras mutation agnostic mechanisms of action that positions us to address a broader range of patients.
This broad potential is highlighted by data from the phase one to a trial that showed each responding patient.
With a different underlying K Ras mutation Barry.
In addition, I should note that two of the responding patients.
Dk 11 co mutations.
Which are generally indicative of a very poor prognosis with currently available treatments.
Complementing these efficacy data from the trial are safety results showing that the study doublet was generally well tolerated.
Looking forward, we are eager to enroll additional patients in the trial and anticipate reporting updated data in the first half of 2023 to inform the continued development of Regal took note of that combination and K Ras mutated non small cell.
Lung cancer.
Beyond lung cancer. We are also planning for the initiation of the investigator sponsored.
Trial in malignant melanoma.
<unk> referenced earlier.
The encouraging lung cancer data, we reported at ESMO are actually supportive of our efforts here as well as both trials.
To evaluate <unk> in combination with anti PD, one therapy in patients refractory to checkpoint inhibition.
With that pipeline.
I will now turn the call over to Mark Karen to discuss our financial results.
Alright.
Thank you Mark.
I'm happy to report that aren't going to finish the quarter ending September 32022, with cash and cash equivalents of $42 6 million.
Compares to $55 1 million as of December 31, 2021.
Based on our current projections, we believe our cash position will be sufficient to fund our ongoing clinical trials and operations, including the pursuit of corporate development opportunities into 2024, thereby taking us through key catalysts expected across the pipeline.
Turning now to our financial results research and development expenses for the third quarter of 2022% or $3 6 million compared to $1 8 million for the third quarter of 2021.
General and administrative expenses for the third quarter of 2022 were $2 1 million and this compares with $2 3 million for the third quarter of 2021.
We reported a net loss for the third quarter of 2022 of $5 4 million or <unk> 26 per share on 29 million weighted shares outstanding.
This compared with a net loss for the third quarter of 2021 of $3 5 million or <unk> <unk> per share on 16 million weighted shares outstanding.
My Financial review complete I will now turn the call back over to Steve.
Okay.
Thank you Barbara.
Before opening up the call for questions I'd like to briefly review the near term value drivers we are approaching.
Looking first at Nevada is a cyclic.
We expect to initiate our phase one slash two a study.
Endometrial cancer in the first quarter of next year.
And report preliminary data in the fourth quarter of 'twenty to 'twenty three.
In the first half of 2023, we expect to identify a recommended phase II dose.
As a cyclist to inform its further development multiple indications.
With <unk>, we are expecting additional data from the investigator sponsored the Golar Mab combination study.
K Ras mutated non small cell lung cancer in the first half of 2023.
We expect to initiate an investigator sponsored study in metastatic malignant melanoma evaluating <unk> in combination with the PD one inhibitor primarily the Mac.
We are extremely pleased with the results seen in the squamous cell carcinoma trial complicating our debt.
Patients who have few if any therapeutic options at work and we have already seen a complete response in our trial with single agent <unk>.
We believe this is extraordinary.
There is non dilutive funding to help finance the trial and we plan to report on additional patients already entered onto the current trial at the appropriate time at a major medical meeting.
As we seek to generate value.
With these programs.
We will continue to devote our internal resources, primarily tuner as a cyclic leveraging investigators sponsored studies and collaboration.
Facilitate negotiated.
Continued progress.
In addition, we will continue to assess opportunities.
Attention to expand our pipeline guided by a data driven approach that focuses on assets backed by robust scientific evidence demonstrating their potential indications with high unmet medical needs.
We are fortunate.
They have a robust financial foundation in place as we pursue these various avenues for value creation.
And eager eager.
Our developing novel solutions for patients with cancers.
Finally, I'd like to briefly thank those behind the progress we reported today.
This stocks first and foremost with our clinical trial participants and also includes our employees partners investigators and shareholders.
With that.
We'll now open up the <unk>.
Two questions.
Operator, ladies.
Ladies and gentlemen, if you wish to register for a question for todays question and answer session. You will need to press Star then the number one on your telephone keypad.
If your question has been answered and you wish to retro your request you may do so by again pressing star one.
If you are using speakerphone, please pick up your handset before entering your request one moment.
Please for the first question.
Charles <unk> with Guggenheim Securities. Your line is open.
Hey, good evening everyone.
My first question regarding the <unk> clip combination with Letrozole, how should we think about the cadence.
<unk> dose escalate accretion in this combination relative to what you guys already did for the single agent dose escalation will you need to escalate in combination just like you did a single agent or could you, possibly start dx escalation to higher given your prior experience. Thanks.
I'll ask Dr. Gallagher Mark please.
So this has been discussed.
Extensively and so you can probably imagine.
And.
Because of the experience with the other CDK <unk> inhibitors in their combination with left resolved in breast cancer.
The current protocol.
We will initiate we're going to start the phase one.
Most of.
Normally the cycle.
At 200 milligrams a day.
Is where we are.
Now.
In the fifth dosing cohort.
And so we.
Don't see any problems. So that we will combine this with less resolved two five milligrams every day, which is the.
Usual approved dose of <unk>.
Got it okay, great that makes sense sorry go on.
And dose escalation will proceed in 40 milligram.
So we'll do the 200 plus letrozole.
Assuming that's well tolerated et cetera will then you moved to 40, plus let's resolve et cetera will not only be looking at PK and safety, but also the PD marker.
<unk> assay from biotech at Teekay one asset.
I just want to add and highlight to make sure everybody knows this delta gilder.
We are very fortunate to have it and I want to highlight his background not everybody may know this block is superbly trained and experienced.
Surgical gynecologic oncologist, having worked at some of the major medical centers in our country, leading their efforts and one that's why we're so pleased to have block <unk>.
Our chief Medical officer for his expertise and Joanne oncology just wanted to highlight that for.
People on the call.
Great and maybe one more follow up given that the other CDK inhibitors have generated proof of concept data, but it doesn't appear that they are approved in this particular setting what do you think you would need to demonstrate in comp.
Combination of what do you think would be considered a win thank you.
Again, though.
So we will look carefully at the data from the phase <unk> study.
But based on the data with the available agents, we would expect that a.
Median PFS of.
Eight to nine months would be a clear win because when you look at historical data.
With <unk> or other quote unquote anti F. <unk> as single agents in this setting it's generally the PFS is in three to four month range.
Great. Thanks for taking the questions.
The man with Ladenburg Thalmann. Your line is open.
Good evening. Thank you so much for taking my question. My question is also on <unk>.
Lip program.
Have you shown any beta from endometrial cancers as a single agent activity and what did it look like if you could comment on that.
So we don't have any data with <unk> cyclic as a single agent.
In endometrial cancer.
And.
If you.
Look at the work that's been done in <unk>.
Batesville cancer with the other CDK four sixes, they've all combined with an aromatase inhibitor electrical.
Hi, Thanks, and my follow up question is public park clips. So a promising data proof of concept. It was HR positive. Thank you Dmitry on cancer are you planning to target and that particular population or are you going to have a broad there.
Endometrial patient enrollment.
So we're our patient population will be patients with low grade <unk> grade, one or grade two endometrial aid endometrial cancer and historically if you look at this population.
90, 790, 899% of them are.
Eftychia receptor positive.
ER positivity.
Is not routinely performed on all patients with endometrial cancer, Unlike breast cancer and the actual threshold for quote unquote endometrial or estrogen receptor positivity is not well established for endometrial cancer like it is for breast <unk>.
Cancer.
So this is why.
We have.
Decided to move forward with this population after consultation with lots of other experts in this area.
Very helpful. Thank you so much for taking my question.
Hello.
Robert Leboyer with noble capital your line is open.
Good afternoon.
My question I thought may have been answered by Dr. Garen.
I thought I may have heard that the dosing regimen is going to be every day compared with three on three off is that correct.
Yes.
Rob if I may.
So based on the data we have so far and we believe.
For reasons, we discussed we prefer not having the one week off scheme.
Sure.
Okay.
Our required because of bone marrow suppression.
In the U S. Our studies every day.
And to date, we do not see significant marrow suppression. We believe we are already targeting the key tyrosine kinase can we do see some lowering of the Wildcat, which is anticipated with this class of drugs, but not to the degree that anything needs to be.
Done.
So we believe and anticipate they will have what I'll call the optimal dose, which will be every day and also once a day everyday dosing to optimize the anti tumor.
Perfect and because of the safety seen to date and in preclinical models as well, we do not have not seen significant toxicity.
Okay.
Okay, great. Thank you and just one other financial question is.
In the R&D expense line.
There was a bit of an increase this quarter over the first half.
And I was wondering if you could give some guidance as to what it might look like going forward for the next several quarters.
Okay.
Mark Guerin.
Sure thing Robert Yes.
Wasn't increase and research and development expenses.
As you can see if you look at our 10-Q, a big chunk of that compared to last year. At this time was related to manufacturing.
During the third quarter of 2022.
You probably know that our historic quarterly cash burn rate has been around four to $4 2 million.
And as we embark on this phase <unk> combination study naturally that's going to go up our current studies, our phase one and or investigator sponsored so once we get back into sponsored studies, our burn will go up.
On a quarterly basis, and so that the only guidance that we're comfortable giving at this point is what we said in the in the press release and in my comment that we believe based on our current cash and our plans that our cash will get us into 'twenty four.
Hopefully thats helpful.
Yes. It is thank you very much.
Sure.
I'm showing no further questions in the queue at this time I would like to turn the call back over to the speakers for any closing remarks.
Okay.
Thank you operator.
And thanks again to all our joined us today.
It's been our pleasure.
Update you on the progress and newly announced plans to pursue near as this cycle in the development.
Endometrial cancer and to update you on the very encouraging clinical data, we have seen and presenting with me as well.
We look forward to providing additional updates in the future.
As the Thanksgiving holiday approaches.
Much to be thankful for.
Yeah sure thanks to the brave patients.
Consent to participating on our experimental studies.
And to our investors, who support our science and helping to bring new therapeutics to those in need.
We wish all of you.
Very lovely evening and thank you again.
Ladies and.
Gentlemen, thank you for your participation on today's conference call. This concludes today's event you may now disconnect.
[music].
Yes.
Okay.
Okay.
Thank you.
[music].
Okay.
[music].
[music].
[music].
[music].
Ladies and gentlemen, thank you for standing by and welcome to the uncle and over Therapeutics third quarter 2022 financial results and business update conference call. At this time, all participants are in a listen only mode.
Following managements prepared remarks, we will hold a question and answer session to ask a question at that time. Please press star followed by the number one on your telephone keypad.
If anyone has any difficulty hearing the conference. Please press star zero for operator assistance.
A reminder, this call is being recorded today November 14th 2022 at this time I would like to turn the call over to Bruce Spackle of lifestyle advisors.
Thank you operator, and welcome everyone to often out of its third quarter 2022 financial results and business.
Update conference call.
Earlier this afternoon <unk> issued a press release announcing its plans to conduct a phase <unk> clinical trial of Lovaza cyclic combined with left result in endometrial cancer.